Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
AKEBIA THERAPEUTICS, INC.
akebia.comAI Executive Summary
AI-powered analysis of 8-K filing content
Akebia Therapeutics announced the resignation of Class I director Steven C. Gilman, Ph.D., effective April 1, 2026, and appointed Philip J. Vickers, Ph.D. as his successor. This routine board transition reflects the company's commitment to refreshing board composition and governance.
Key Takeaways
Steven C. Gilman resigned from the Board effective April 1, 2026, with no disagreements cited regarding company operations or policies
Philip J. Vickers, Ph.D. was elected as Class I director to replace Gilman, with a term expiring at the 2027 annual stockholder meeting
2 more takeaways
Related Filings (2)
2 more filings from AKEBIA THERAPEUTICS, INC. in the last 90 days